



IDT is leveraging its decades of experience in drug development and manufacture into its own range of specialty generic drugs for sale in the US market. IDT recently acquired 23 approved US generic drugs, the total addressable market of which is US\$460 million. IDT has begun work on transferring these products into its state-of-the-art Melbourne manufacturing facilities and to prepare the dossiers for product launches targeting CY2016 onwards. IDT is looking for potential US distribution partners. In addition, IDT filed its first ANDA in December 2013 for temozolomide, a generic oncology drug with an addressable market of over US\$200 million. Approval for temozolomide was received in early 2016 ahead of expectations.

With over 35 years' experience and an impressive global regulatory track record, IDT has developed over 115 products for our customers, including 9 of the top 10 pharmaceutical companies worldwide. IDT helps pharmaceutical, medical device and biotech companies fast-track products through all stages of development, from R&D through to clinical trials.

We specialize in developing & manufacturing complex, highly potent drugs, beta-lactam antibiotics & cytotoxic products at our site in Melbourne, and running First Time in Human and other Phase I clinical trials at CMAX, Australia's largest and most experienced clinical trials unit.